神威藥業(02877.HK)附屬向關連方提供技術服務 代價1,400萬人幣
神威藥業集團(02877.HK)公布,間接全資附屬神威藥業與神威醫藥簽訂一份有關由神威醫藥向神威藥業提供服務的技術服務合同,向對方提供與項目(塞絡通膠囊Ⅲ期臨床試驗)有關的技術服務,包括但不限於,項目管理、監查及質控項目的進度和過程,篩選中心實驗室及冷鏈運輸公司,配備參研單位及相關技術人員,監查及向技術人員及研究人員提供培訓(費用由神威醫藥支付) ,準備及文檔管理相關文件,及定期向神威藥業報告,技術服務合同代價為1,400萬元人民幣。
公司執行董事李振江的配偶任俊英間接持有神威醫藥的100%權益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.